Company Filing History:
16 out of 17 
5 out of 8 
1 out of 1 Years Active: 1989-2014
Title: Stephen Grimes: Innovator in Monoclonal Antibody Therapies
Introduction: Stephen Grimes is an accomplished inventor based in Davis, California, with an impressive portfolio of 22 patents to his name. His work primarily focuses on the development of therapeutic strategies to combat diseases related to gastrin, including pancreatic cancer. Grimes exemplifies the role of innovation in the field of biotechnology.
Latest Patents: Among his latest contributions, Grimes has developed monoclonal antibodies that specifically bind to progastrin. This invention aims to provide therapeutic options for passive immunization against progastrin in gastrin-promoted diseases or conditions. Notably, these progastrin-binding molecules do not interact with alternative forms of gastrin, including gastrin-17, gastrin-34, glycine-extended gastrin-17, or glycine-extended gastrin-34. His work also encompasses a combination treatment for pancreatic cancer, showcasing a commitment to addressing significant medical challenges through innovative research.
Career Highlights: Grimes has played a crucial role in various companies, including Aphton Corporation and Cancer Advances, Inc. His career has centered around utilizing his expertise in antibody development and oncology to drive forward impactful healthcare solutions.
Collaborations: Throughout his career, Grimes has collaborated with notable colleagues, such as Philip C. Gevas and Stephen L. Karr. These partnerships have enhanced his research capabilities and have been instrumental in advancing his innovations in antibody therapies.
Conclusion: Stephen Grimes continues to make significant strides in the field of biotechnology through his patented inventions and collaborations. His focus on monoclonal antibodies positions him as a leading inventor in the fight against gastrin-related diseases, including pancreatic cancer, thus contributing to the advancement of medical science and patient care.